(see Nature 519, 272; 2015) . But in the nonreproductive cells of children and adults, where inter generational issues are not a concern, researchers and companies are already racing to develop CRISPR as a clinical tool.
The ethics of that pursuit may be more straightforward, but its execution can be harder than using CRISPR in embryos. An embryo consists of a small number of cells that give rise to a human. To edit the genome at that stage is simply a matter of injecting the necessary CRISPR components into a few cells. An adult human, however, is a mix of trillions of cells assembled into many different tissues. Researchers fret over how to target the CRISPR machinery to the specific cells where defective genes are disrupting physiological processes.
"You can have the most optimal gene-editing system in the world, but if you can't deliver it to the proper cell type, it's irrelevant, " says Nessan Bermingham, chief executive of Intellia Therapeutics in Cambridge, Massachusetts, which aims to bring genome editing to the clinic. "We're spending a tremendous amount of time working on it. "
SNUG FIT
Gene-therapy researchers often harness a virus called AAV to shuttle foreign genes into mature human cells. However, most laboratories use a gene encoding the Cas9 protein that is too large to fit in the snug confines of the AAV genome alongside the extra sequences necessary for Cas9 function.
CORRECTIONS
The News Feature 'Eyes on the ocean' (Nature 519, 280-282; 2015) Feng Zhang of the Broad Institute of MIT and Harvard in Cambridge, Massachusetts, and his colleagues decided to raid bacterial genomes for a solution, because the CRISPR system is derived from a process that bacteria use to snip unwanted DNA sequences out of their genomes. Zhang's team analysed genes encoding more than 600 Cas9 enzymes from hundreds of bacteria in search of a smaller version that could be packaged in AAV and delivered to mature cells.
The gene encoding Cas9 in Staphylococcus aureus -a bacterium best known for causing skin infections and food poisoning -was more than 1,000 DNA letters smaller than the one for the commonly used Cas9. The researchers packed it into AAV along with RNAs that would target the enzyme to modify a cholesterol regulatory gene in the liver. Within a week of injecting mice with the modified virus, the team found that more than 40% of liver cells contained the modified gene. "It's a terrific addition to the set of tools that genome engineers have at their disposal, " says Liu. He has been developing ways to transport the larger Cas9 protein, bound to its guide RNAs, into cells without relying on a virus. Bermingham says that he expects labs to develop multiple delivery mechanisms that are tailored to individual tissues.
For now, biomedical engineer Charles Gersbach of Duke University in Durham, North Carolina, is eager to use the smaller Cas9 enzyme in mice to try to correct mutations associated with Duchenne muscular dystrophy, a devastating human disease that strikes 1 in 3,500 boys worldwide. Perhaps this will be the method that carries CRISPR into the clinic, he says, but it is too soon to tell. "It's a rapidly developing field, " he says. "There are a lot of things that just haven't been tried yet. 
